6.0 Summary of All Research Findings - Index

6.0.1 Index of Summaries

Key Area	Section	Title
Health Risks of the Tobacco Product	6.1.1	Aerosol Chemistry and Physics
	6.1.2	Pre-clinical Safety Toxicology
	6.1.3.1	Justification of Selection of Biomarkers of Exposure
	6.1.3.2	Summary of Biomarkers of Exposure Assessments
	6.1.3.3	Bioanalytical Methods
	6.1.3.4	Reduced Exposure - Overview of Studies
	6.1.4	Clinical Risk Endpoints
	6.1.5	Human Safety Summary
	6.1.6	Conclusions on Health Risk of the Tobacco Product
Effect on Tobacco Use Behavior among Current Users	6.2.1.1	Summary of Clinical Pharmacology Studies
	6.2.1.2	PK/PD Overview of Studies
	6.2.2	Product Usage Assessment among CC smokers
	6.2.3	Abuse Liability Summary
	6.2.4	Overall Conclusions on Tobacco Use Behavior among Current Tobacco Users
Effect on Tobacco Use Initiation among Non-Users	6.3.1	Intent to Use Among Tobacco Non-Users
	6.3.2	Epidemiological Evidence of Tobacco Use in the US
	6.3.3	Conclusions on the Effect of THS on Tobacco Use Initiation among Non-Users

(table continues)

Confidentiality Statement

Confidentiality Statement: Data and information contained in this document are considered to constitute trade secrets and confidential commercial information, and the legal protections provided to such trade secrets and confidential information are hereby claimed under the applicable provisions of United States law. No part of this document may be publicly disclosed without the written consent of Philip Morris International.

Key Area	Section	Title
Effect of Marketing on Consumer Understanding and Perceptions	6.4	Effect of Marketing on Consumer Understanding and Perceptions
Effect on the Population as a Whole	6.5	Effect on the population as a whole

Confidentiality Statement

Confidentiality Statement: Data and information contained in this document are considered to constitute trade secrets and confidential commercial information, and the legal protections provided to such trade secrets and confidential information are hereby claimed under the applicable provisions of United States law. No part of this document may be publicly disclosed without the written consent of Philip Morris International.

6.0.2 Index of Studies and Analyses

Key Area	Study Type	Section, Summary and Index of Studies
6.1 Health Risks of the Tobacco Product	Product Analyses	7.1 Executive Summary – Product Characterization Studies 7.1 Tabulated Index of Product Characterization Studies
	Nonclinical Studies	7.2 Executive Summary – Pre-clinical Studies 7.2 Tabulated Index of Pre-clinical Studies 7.5 Executive Summary – Mechanistic and Systems Toxicology Studies 7.5 Tabulated Index of Mechanistic and Systems Toxicology (SYSTOX) Studies
	Studies in Adult Human Subjects	7.3.1 Executive Summary – Clinical Studies 7.3.1 Tabulated Index of Clinical Studies
6.2 Effect on Tobacco Use Behavior among Current Users	Studies in Adult Human Subjects	7.3.1 Executive Summary – Clinical Studies 7.3.1 Tabulated Index of Clinical Studies 7.3.2 Executive Summary – Premarket Perception and Behavior Assessment Program 7.3.2 Tabulated Index of Perception and Behavior Assessment (PBA) Studies 7.3.3 Executive Summary – Whole Offer Test Studies 7.3.3 Tabulated Index of Whole Offer Test Studies

(table continues)

Confidentiality Statement

Confidentiality Statement: Data and information contained in this document are considered to constitute trade secrets and confidential commercial information, and the legal protections provided to such trade secrets and confidential information are hereby claimed under the applicable provisions of United States law. No part of this document may be publicly disclosed without the written consent of Philip Morris International.

Key Area	Study Type	Section, Summary and Index of Studies
6.3 Effect on Tobacco Use Initiation among Non-Users	Studies in Adult Human Subjects	7.3.2 Executive Summary – Premarket Perception and Behavior Assessment Program 7.3.2 Tabulated Index of Perception and Behavior Assessment (PBA) Studies
6.4 Effect of Marketing on Consumer Understanding and Perceptions	Studies in Adult Human Subjects	7.3.2 Executive Summary – Premarket Perception and Behavior Assessment Program 7.3.2 Tabulated Index of Perception and Behavior Assessment (PBA) Studies
6.5 Effect on the Population as a Whole	Secondary data and analyses modeling	7.4 Executive Summary – Population Health Impact Model studies 7.4 Tabulated Index of Population Health Impact Model (PHIM) studies

Confidentiality Statement

Confidentiality Statement: Data and information contained in this document are considered to constitute trade secrets and confidential commercial information, and the legal protections provided to such trade secrets and confidential information are hereby claimed under the applicable provisions of United States law. No part of this document may be publicly disclosed without the written consent of Philip Morris International.